Best Niche Antibody-based Biologics


John Ripple

John Ripple was the CEO of Exonics Therapeutics which was acquired by Vertex Pharmaceuticals. Prior to Exonics, John served as CEO of Ensemble, Permeon, Virdante, and Syntonix. John founded Ripple Biotech to advise biopharmaceutical companies on strategy, business development as well as fundraisings. John received a Bachelor degree in Mechanical Engineering from Bucknell University and an MBA from Harvard Business School.